The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
RAS-mediated oncogenic signaling pathways in human malignancies
Abstract
Abnormally activated RAS proteins are the main oncogenic driver that governs the functioning of major signaling pathways involved in the initiation and development of human malignancies. Mutations in RAS genes and or its regulators, most frequent in human cancers, are the main force for incessant RAS activation and associated pathological conditions including cancer. In general, RAS is the main upstream regulator of the highly conserved signaling mechanisms associated with a plethora of important cellular activities vital for normal homeostasis. Mutated or the oncogenic RAS aberrantly activates a web of interconnected signaling pathways including RAF-MEK (mitogen-activated protein kinase kinase)-ERK (extracellular signal-regulated kinase), phosphoinositide-3 kinase (PI3K)/AKT (protein kinase B), protein kinase C (PKC) and ral guanine nucleotide dissociation stimulator (RALGDS), etc., leading to uncontrolled transcriptional expression and reprogramming in the functioning of a range of nuclear and cytosolic effectors critically associated with the hallmarks of carcinogenesis. This review highlights the recent literature on how oncogenic RAS negatively use its signaling web in deregulating the expression and functioning of various effector molecules in the pathogenesis of human malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., Kamphorst, J. J., Chen, G., Lemons, J. M. S., Karantza, V., et al. (2011) · Genes & Development · doi:10.1101/gad.2016311 · Cited by 1,323
Transcription factors as targets for cancer therapy
Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Croce, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072367 · Cited by 1,055
Dynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
Matsusaka, T., Fujikawa, K., Nishio, Y., Mukaida, N., Matsushima, K., Kishimoto, T., & Akira, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10193 · Cited by 959
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
Staudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
STAT3 Plays a Critical Role in KRAS -Induced Pancreatic Tumorigenesis
Corcoran, R. B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes, C. H., Levy, D. E., Settleman, J., Engelman, J. A., & Bardeesy, N. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0908 · Cited by 413
Papke, B., & Der, C. J. (2017) · Science · doi:10.1126/science.aam7622 · Cited by 399
Oncogenic Kras drives invasion and maintains metastases in colorectal cancer
Boutin, A. T., Liao, W.-T., Wang, M., Hwang, S. S., Karpinets, T. V., Cheung, H., Chu, G. C., Jiang, S., Hu, J., Chang, K., et al. (2017) · Genes & Development · doi:10.1101/gad.293449.116 · Cited by 195
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
Kim, W. Y., Perera, S., Zhou, B., Carretero, J., Yeh, J. J., Heathcote, S. A., Jackson, A. L., Nikolinakos, P., Ospina, B., Naumov, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38443 · Cited by 141
Quilliam, L. A., Castro, A. F., Rogers-Graham, K. S., Martin, C. B., Der, C. J., & Bi, C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.23850 · Cited by 119
RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer
Yan, C., & Theodorescu, D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014415 · Cited by 119
Chun, S. Y., Johnson, C., Washburn, J. G., Cruz-Correa, M. R., Dang, D. T., & Dang, L. H. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-293 · Cited by 109
Ral signaling pathway in health and cancer
Moghadam, A. R., Patrad, E., Tafsiri, E., Peng, W., Fangman, B., Pluard, T. J., Accurso, A., Salacz, M., Shah, K., Ricke, B., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1105 · Cited by 58
Research works printed but not linked: 207
- Rojas, 2012, The Ras protein superfamily: evolutionary tree and role of conserved amino acids, J. Cell Biol., 196, 189, 10.1083/jcb.201103008 · DOI · Paper page
- Wennerberg, 2005, The Ras superfamily at a glance, J. Cell Sci., 118, 843, 10.1242/jcs.01660 · DOI · Paper page
- Ward, 2012, Targeting oncogenic Ras signaling in hematologic malignancies, Blood, 120, 3397, 10.1182/blood-2012-05-378596 · DOI · Paper page
- Vigil, 2010, Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy, Nat. Rev. Cancer, 10, 842, 10.1038/nrc2960 · DOI · Paper page
- Zhou, 2016, The role of wild type RAS isoforms in cancer, Semin. Cell Dev. Biol., 58, 60, 10.1016/j.semcdb.2016.07.012 · DOI · Paper page
- Mann, 2016, KRAS-related proteins in pancreatic cancer, Pharmacol. Ther., 168, 29, 10.1016/j.pharmthera.2016.09.003 · DOI · Paper page
- LeBleu, 2013, Origin and function of myofibroblasts in kidney fibrosis, Nat. Med., 19, 1047, 10.1038/nm.3218 · DOI · Paper page
- Logsdon, 2016, The significance of Ras activity in pancreatic cancer initiation, Int. J. Biol. Sci., 12, 338, 10.7150/ijbs.15020 · DOI
- Baines, 2011, Inhibition of Ras for cancer treatment: the search continues, Future Med. Chem., 3, 1787, 10.4155/fmc.11.121 · DOI · Paper page
- Rodenhuis, 1992, Ras and human tumors, Semin. Cancer Biol., 3, 241
- Mengoli, 2016, K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: report of two cases and review of the literature, Lung Cancer, 93, 55, 10.1016/j.lungcan.2016.01.002 · DOI
- Beaupre, 1999, RAS and leukemia: from basic mechanisms to gene-directed therapy, J. Clin. Oncol., 17, 1071, 10.1200/JCO.1999.17.3.1071 · DOI · Paper page
- Bahrami, 2018, The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer, J. Cell. Physiol., 233, 2162, 10.1002/jcp.25952 · DOI
- Martinelli, 2017, Cancer resistance to therapies against the EGFR-RAS-RAF pathway: the role of MEK, Cancer Treat. Rev., 53, 61, 10.1016/j.ctrv.2016.12.001 · DOI
- Coelho, 2017, Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA, Immunity, 47, 1083, 10.1016/j.immuni.2017.11.016 · DOI · Paper page
- Chin, 1999, Essential role for oncogenic Ras in tumour maintenance, Nature, 400, 468, 10.1038/22788 · DOI · Paper page
- Knickelbein, 2015, Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer, Genes Dis., 2, 4, 10.1016/j.gendis.2014.10.002 · DOI
- Barbacid, 1987, Ras genes, Annu. Rev. Biochem, 56, 779, 10.1146/annurev.bi.56.070187.004023 · DOI · Paper page
- Cohen, 1989, Expression of the H-ras proto-oncogene is controlled by alternative splicing, Cell, 58, 461, 10.1016/0092-8674(89)90427-3 · DOI
- Seeburg, 1984, Biological properties of human c-Ha-ras1 genes mutated at codon 12, Nature, 312, 71, 10.1038/312071a0 · DOI · Paper page
- Bos, 1989, Ras oncogenes in human cancer: a review, Cancer Res., 49, 4682
- Parsons, 2002, Occurrence of H-ras codon 61 CAA to AAA mutation during mouse liver tumor progression, Carcinogenesis, 23, 943, 10.1093/carcin/23.6.943 · doi:10.1093/carcin/23.6.943
- Smith, 2010, Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours–implications for personalised cancer medicine, Br. J. Cancer, 102, 693, 10.1038/sj.bjc.6605534 · DOI · Paper page
- Johnson, 2001, Somatic activation of the K-ras oncogene causes early onset lung cancer in mice, Nature, 410, 1111, 10.1038/35074129 · DOI · Paper page
- Stolze, 2015, Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines, Sci. Rep., 5, 8535, 10.1038/srep08535 · DOI
- Phipps, 2013, KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers, Br. J. Cancer, 108, 1757, 10.1038/bjc.2013.118 · DOI · Paper page
- Imamura, 2012, Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers, Clin. Cancer Res., 18, 4753, 10.1158/1078-0432.CCR-11-3210 · DOI · Paper page
- Edkins, 2006, Recurrent KRAS codon 146 mutations in human colorectal cancer, Cancer Biol. Ther., 5, 928, 10.4161/cbt.5.8.3251 · DOI · Paper page
- Omholt, 2002, Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression, Clin. Cancer Res., 8, 3468
- Irahara, 2010, NRAS mutations are rare in colorectal cancer, Diagn. Mol. Pathol., 19, 157, 10.1097/PDM.0b013e3181c93fd1 · DOI · Paper page
- Matsumoto, 1997, Novel small GTPase M-Ras participates in reorganization of actin cytoskeleton, Oncogene, 15, 2409, 10.1038/sj.onc.1201416 · DOI
- Huff, 1997, R-Ras is regulated by activators and effectors distinct from those that control Ras function, Oncogene, 14, 133, 10.1038/sj.onc.1200815 · DOI
- Fernandez-Medarde, 2011, Ras in cancer and developmental diseases, Genes Cancer, 2, 344, 10.1177/1947601911411084 · DOI · Paper page
- Caldas, 1994, Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia, Cancer Res., 54, 3568
- Lu, 2017, Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas, PLoS One, 12, e0181532, 10.1371/journal.pone.0181532 · DOI
- Lee, 2016, KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis, SpringerPlus, 5, 1172, 10.1186/s40064-016-2847-4 · DOI
- Hashimoto, 2016, Heterogeneity of KRAS mutations in pancreatic ductal adenocarcinoma, Pancreas, 45, 1111, 10.1097/MPA.0000000000000624 · DOI
- Miglio, 2014, KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance, Pathol. Res. Pract., 210, 307, 10.1016/j.prp.2014.01.011 · DOI
- Sinn, 2014, KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma, Pancreas, 43, 578, 10.1097/MPA.0000000000000077 · DOI
- Forbes, 2011, COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer, Nucleic Acids Res., 39, D945, 10.1093/nar/gkq929 · DOI · Paper page
- Immervoll, 2006, Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes, Virchows Arch., 448, 788, 10.1007/s00428-006-0191-8 · DOI
- Kawesha, 2000, K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma, Int. J. Cancer, 89, 469, 10.1002/1097-0215(20001120)89:6<469::AID-IJC1>3.0.CO;2-L · DOI
- Whyte, 1997, K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors, J. Biol. Chem., 272, 14459, 10.1074/jbc.272.22.14459 · DOI · Paper page
- Weden, 2011, Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras, Int. J. Cancer, 128, 1120, 10.1002/ijc.25449 · DOI · Paper page
- Poulin, 2017, No back seat for a progression event-K-RAS as a therapeutic target in CRC, Genes Dev., 31, 333, 10.1101/gad.297630.117 · DOI
- Abubaker, 2009, Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma, J. Pathol., 219, 435, 10.1002/path.2625 · DOI
- Lievre, 2018, RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: a status report in 2014, Dig. Liver Dis., 10.1016/j.dld.2017.12.029 · DOI
- Petaccia de Macedo, 2017, KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care, Am. J. Cancer. Res., 7, 1978
- Zekri, 2017, Mutations in codons 12 and 13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients: frequency, clincopathological associations, and clinical outcomes, Genet. Mol. Res., 16, 10.4238/gmr16019369 · DOI
- Kafatos, 2017, RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data, Biomark. Med., 10.2217/bmm-2016-0358 · DOI
- Vogelstein, 1988, Genetic alterations during colorectal-tumor development, N. Engl. J. Med., 319, 525, 10.1056/NEJM198809013190901 · DOI · Paper page
- Chang, 2016, Mutation spectra of RAS gene family in colorectal cancer, Am. J. Surg., 212, 537, 10.1016/j.amjsurg.2016.02.013 · DOI
- Conlin, 2005, The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma, Gut, 54, 1283, 10.1136/gut.2005.066514 · DOI · Paper page
- Dinu, 2014, Prognostic significance of KRAS gene mutations in colorectal cancer–preliminary study, J. Med. Life, 7, 581
- Lohinai, 2017, KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis, Sci. Rep., 7, 39721, 10.1038/srep39721 · DOI
- Cejas, 2009, KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis, PLoS One, 4, e8199, 10.1371/journal.pone.0008199 · DOI
- Lievre, 2008, KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J. Clin. Oncol., 26, 374, 10.1200/JCO.2007.12.5906 · DOI · Paper page
- Raponi, 2008, KRAS mutations predict response to EGFR inhibitors, Curr. Opin. Pharmacol., 8, 413, 10.1016/j.coph.2008.06.006 · DOI
- Saif, 2009, Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas, Cancer J., 15, 339, 10.1097/PPO.0b013e3181b36264 · DOI
- Howell, 2013, RAS mutations in thyroid cancer, Oncologist, 18, 926, 10.1634/theoncologist.2013-0072 · DOI · Paper page
- Bhaijee, 2011, Molecular analysis of thyroid tumors, Endocr. Pathol., 22, 126, 10.1007/s12022-011-9170-y · DOI
- Abubaker, 2008, Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population, J. Clin. Endocrinol. Metab., 93, 611, 10.1210/jc.2007-1717 · DOI · Paper page
- Latteyer, 2016, Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer, Endocrine, 54, 733, 10.1007/s12020-016-1080-9 · doi:10.1007/s12020-016-1080-9
- Duman, 2014, Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma, Contemp. Oncol. (Pozn.), 18, 234
- Fakhruddin, 2017, BRAF and NRAS mutations in papillary thyroid carcinoma and concordance in BRAF mutations between primary and corresponding lymph node metastases, Sci. Rep., 7, 4666, 10.1038/s41598-017-04948-3 · doi:10.1038/s41598-017-04948-3
- Wells, 2009, Targeting the RET pathway in thyroid cancer, Clin. Cancer Res., 15, 7119, 10.1158/1078-0432.CCR-08-2742 · DOI · Paper page
- Lee, 2010, Complications of radioactive iodine treatment of thyroid carcinoma, J. Natl. Compr. Cancer Netw., 8, 1277, 10.6004/jnccn.2010.0094 · DOI
- Hong, 2009, Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies, Clin. Cancer Res., 15, 7061, 10.1158/1078-0432.CCR-09-1241 · DOI
- Reuter, 2000, Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies, Blood, 96, 1655, 10.1182/blood.V96.5.1655 · DOI · Paper page
- Wang, 2010, Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia, Blood, 116, 5991, 10.1182/blood-2010-04-281527 · DOI
- Zhou, 2017, KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia, Oncotarget, 8, 66087, 10.18632/oncotarget.19798 · DOI
- Liang, 2018, Mutational status of NRAS, KRAS, and PTPN 11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia, Pediatr. Blood Cancer, 65, 10.1002/pbc.26786 · DOI
- De Melo, 1997, N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis, Leuk. Lymphoma, 24, 309, 10.3109/10428199709039018 · DOI
- Kiyoi, 1999, Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia, Blood, 93, 3074
- Shih, 2004, Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia, Leukemia, 18, 466, 10.1038/sj.leu.2403274 · DOI
- Lubbert, 1990, N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis, Blood, 75, 1163, 10.1182/blood.V75.5.1163.1163 · DOI
- Paquette, 1993, N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome, Blood, 82, 590, 10.1182/blood.V82.2.590.590 · DOI · Paper page
- Marin, 2010, Current status of imatinib as frontline therapy for chronic myeloid leukemia, Semin. Hematol., 47, 312, 10.1053/j.seminhematol.2010.06.003 · DOI
- Timar, 2014, The clinical relevance of KRAS gene mutation in non-small-cell lung cancer, Curr. Opin. Oncol., 26, 138, 10.1097/CCO.0000000000000051 · DOI
- Suzuki, 1990, Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products, Oncogene, 5, 1037
- Marabese, 2015, KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy, Oncotarget, 6, 34014, 10.18632/oncotarget.5607 · DOI
- Forest, 2017, EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: value of testing on samples with poor specimen adequacy and analysis of discrepancies, Exp. Mol. Pathol., 103, 306, 10.1016/j.yexmp.2017.11.013 · DOI
- Jia, 2017, Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer, Oncol. Lett., 14, 6525
- Turhal, 2015, Prevalence of K-Ras mutations in hepatocellular carcinoma: a Turkish Oncology Group pilot study, Mol. Clin. Oncol., 3, 1275, 10.3892/mco.2015.633 · DOI
- Ye, 2014, Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice, Oncogene, 33, 5133, 10.1038/onc.2013.468 · DOI
- Hou, 2014, Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma, Oncol. Lett., 8, 1249, 10.3892/ol.2014.2253 · DOI
- Tilch, 2014, Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women, Breast Cancer Res. Treat., 143, 385, 10.1007/s10549-013-2798-1 · DOI
- Cejalvo, 2016, Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer, Breast Cancer Res. Treat., 160, 69, 10.1007/s10549-016-3980-z · DOI
- Wang, 2015, Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai, Genet. Mol. Res., 14, 14840, 10.4238/2015.November.18.49 · DOI
- Uvirova, 2015, Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 159, 466, 10.5507/bp.2015.029 · doi:10.5507/bp.2015.029
- Xing, 2017, Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma, Hum. Pathol., 68, 87, 10.1016/j.humpath.2017.08.021 · doi:10.1016/j.humpath.2017.08.021
- Zannoni, 2016, Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients, J. Clin. Pathol., 69, 1088, 10.1136/jclinpath-2016-203776 · DOI
- Nanus, 1990, Infrequent ras oncogene point mutations in renal cell carcinoma, J. Urol., 143, 175, 10.1016/S0022-5347(17)39905-6 · DOI
- Ponti, 2017, BRAF, NRAS and C-KIT advanced melanoma: clinico-pathological features, targeted-therapy strategies and survival, Anticancer Res., 37, 7043
- Munoz-Couselo, 2017, NRAS-mutant melanoma: current challenges and future prospect, Onco Targets Ther., 10, 3941, 10.2147/OTT.S117121 · DOI · Paper page
- Queirolo, 2017, Binimetinib for the treatment of NRAS-mutant melanoma, Expert Rev. Anticancer Ther., 17, 985, 10.1080/14737140.2017.1374177 · DOI
- Heppt, 2017, Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care, BMC Cancer, 17, 536, 10.1186/s12885-017-3529-5 · DOI
- McDaniel, 2014, HRAS mutations are frequent in inverted urothelial neoplasms, Hum. Pathol., 45, 1957, 10.1016/j.humpath.2014.06.003 · DOI
- Beukers, 2014, HRAS mutations in bladder cancer at an early age and the possible association with the Costello Syndrome, Eur. J. Hum. Genet., 22, 837, 10.1038/ejhg.2013.251 · doi:10.1038/ejhg.2013.251
- Wang, 2012, H-ras mutation detection in bladder cancer by COLD-PCR analysis and direct sequencing, Urol. Int., 88, 350, 10.1159/000336132 · DOI
- Jinesh, 2017, Molecular genetics and cellular events of K-Ras-driven tumorigenesis, Oncogene
- Fey, 2016, The complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells, Semin. Cell Dev. Biol., 58, 96, 10.1016/j.semcdb.2016.06.011 · DOI
- Yang, 2017, Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma, Oncol. Lett., 13, 1041, 10.3892/ol.2017.5557 · DOI · Paper page
- Cseh, 2014, “RAF” neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway, FEBS Lett., 588, 2398, 10.1016/j.febslet.2014.06.025 · DOI
- Imperial, 2017, Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: its clinical implications, Semin. Cancer Biol.
- Dorard, 2017, Deciphering the RAS/ERK pathway in vivo, Biochem. Soc. Trans., 45, 27, 10.1042/BST20160135 · DOI
- Sriskanthadevan-Pirahas, 2018, Ras/ERK-signalling promotes tRNA synthesis and growth via the RNA polymerase III repressor Maf1 in Drosophila, PLoS Genet., 14, e1007202, 10.1371/journal.pgen.1007202 · DOI
- Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, 3, 11, 10.1038/nrc969 · DOI · Paper page
- Sheridan, 2013, Inhibiting the RAS-PI3K pathway in cancer therapy, Enzymes, 34, 107, 10.1016/B978-0-12-420146-0.00005-6 · DOI
- Jankovic, 1996, International conference on chronic myelocytic leukemia: biology and treatment organised by the Scientific Committee of The Israel Society of Hematology, Jerusalem, Israel, 28-31 January 1996, Leukemia, 10, 1667
- Li, 2017, R-Ras-Akt axis induces endothelial lumenogenesis and regulates the patency of regenerating vasculature, Nat. Commun., 8, 1720, 10.1038/s41467-017-01865-x · DOI
- Gagliardi, 2017, PDK1: at the crossroad of cancer signaling pathways, Semin. Cancer Biol.
- Martini, 2014, PI3K/AKT signaling pathway and cancer: an updated review, Ann. Med., 46, 372, 10.3109/07853890.2014.912836 · DOI · Paper page
- Guin, 2015, The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer, Acta Pharmacol. Sin., 36, 291, 10.1038/aps.2014.129 · DOI
- Suryaraja, 2013, The E3 ubiquitin ligase Itch regulates tumor suppressor protein RASSF5/NORE1 stability in an acetylation-dependent manner, Cell Death Dis., 4, e565, 10.1038/cddis.2013.91 · DOI
- Bee, 2010, Growth and tumor suppressor NORE1A is a regulatory node between Ras signaling and microtubule nucleation, J. Biol. Chem., 285, 16258, 10.1074/jbc.M109.081562 · DOI
- Calvisi, 2009, NORE1A tumor suppressor candidate modulates p21CIP1 via p53, Cancer Res., 69, 4629, 10.1158/0008-5472.CAN-08-3672 · DOI
- Stacey, 1984, Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein, Nature, 310, 508, 10.1038/310508a0 · DOI · Paper page
- McCarthy, 1995, Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes, Genes Dev., 9, 1953, 10.1101/gad.9.16.1953 · DOI · Paper page
- Woods, 2001, Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway, Mol. Cell. Biol., 21, 3192, 10.1128/MCB.21.9.3192-3205.2001 · DOI
- Dajee, 2002, Epidermal Ras blockade demonstrates spatially localized Ras promotion of proliferation and inhibition of differentiation, Oncogene, 21, 1527, 10.1038/sj.onc.1205287 · DOI
- Amin, 2015, Evasion of anti-growth signaling: a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds, Semin. Cancer Biol., 35, S55, 10.1016/j.semcancer.2015.02.005 · DOI
- Chen, 2001, Regulation of glut1 mRNA by hypoxia-inducible factor-1: interaction between H-ras and hypoxia, J. Biol. Chem., 276, 9519, 10.1074/jbc.M010144200 · DOI · Paper page
- Blum, 2005, Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death, Cancer Res., 65, 999, 10.1158/0008-5472.999.65.3 · DOI · Paper page
- Semenza, 2007, Hypoxia and cancer, Cancer Metastasis Rev., 26, 223, 10.1007/s10555-007-9058-y · DOI · Paper page
- Flier, 1987, Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes, Science, 235, 1492, 10.1126/science.3103217 · DOI · Paper page
- Shaw, 2006, Glucose metabolism and cancer, Curr. Opin. Cell Biol., 18, 598, 10.1016/j.ceb.2006.10.005 · DOI · Paper page
- Lock, 2011, Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation, Mol. Biol. Cell, 22, 165, 10.1091/mbc.e10-06-0500 · DOI · Paper page
- Kim, 2011, Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation, J. Biol. Chem., 286, 12924, 10.1074/jbc.M110.138958 · DOI · Paper page
- Rak, 2004, Oncogenes and tumor angiogenesis: the question of vascular supply and vascular demand, Semin. Cancer Biol., 14, 93, 10.1016/j.semcancer.2003.09.014 · DOI
- Rak, 1995, Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis, Cancer Res., 55, 4575
- Kranenburg, 2004, Stimulation of angiogenesis by Ras proteins, Biochim. Biophys. Acta, 1654, 23
- Giehl, 2005, Oncogenic Ras in tumour progression and metastasis, Biol. Chem., 386, 193, 10.1515/BC.2005.025 · DOI · Paper page
- Campbell, 2004, Oncogenic Ras and its role in tumor cell invasion and metastasis, Semin. Cancer Biol., 14, 105, 10.1016/j.semcancer.2003.09.015 · DOI · Paper page
- Nebert, 2002, Transcription factors and cancer: an overview, Toxicology, 181–182, 131, 10.1016/S0300-483X(02)00269-X · DOI
- Lee, 2013, Transcriptional regulation and its misregulation in disease, Cell, 152, 1237, 10.1016/j.cell.2013.02.014 · DOI · Paper page
- Dolcet, 2005, NF-kB in development and progression of human cancer, Virchows Arch., 446, 475, 10.1007/s00428-005-1264-9 · DOI · Paper page
- Tilborghs, 2017, The role of Nuclear Factor-kappa B signaling in human cervical cancer, Crit. Rev. Oncol. Hematol., 120, 141, 10.1016/j.critrevonc.2017.11.001 · DOI · Paper page
- Jo, 2000, NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis, Oncogene, 19, 841, 10.1038/sj.onc.1203392 · DOI
- Lee, 2006, H-Ras selectively up-regulates MMP-9 and COX-2 through activation of ERK1/2 and NF-kappaB: an implication for invasive phenotype in rat liver epithelial cells, Int. J. Cancer, 119, 1767, 10.1002/ijc.22056 · DOI
- Sparmann, 2004, Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis, Cancer Cell, 6, 447, 10.1016/j.ccr.2004.09.028 · DOI · Paper page
- Meylan, 2009, Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma, Nature, 462, 104, 10.1038/nature08462 · DOI · Paper page
- Jeay, 2003, Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B, Mol. Cell. Biol., 23, 2251, 10.1128/MCB.23.7.2251-2263.2003 · DOI
- Kim, 2005, NF-kappaB inhibition radiosensitizes Ki-Ras-transformed cells to ionizing radiation, Carcinogenesis, 26, 1395, 10.1093/carcin/bgi081 · DOI
- Mizumoto, 2011, Activation of NF-kappaB is a novel target of KRAS-induced endometrial carcinogenesis, Clin. Cancer Res., 17, 1341, 10.1158/1078-0432.CCR-10-2291 · DOI
- Yu, 2014, Revisiting STAT3 signalling in cancer: new and unexpected biological functions, Nat. Rev. Cancer, 14, 736, 10.1038/nrc3818 · DOI · Paper page
- Huynh, 2017, The JAK/STAT3 axis: a comprehensive drug target for solid malignancies, Semin. Cancer Biol., 45, 13, 10.1016/j.semcancer.2017.06.001 · DOI · Paper page
- Shanmugam, 2016, Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds, Semin. Cancer Biol., 40–41, 35, 10.1016/j.semcancer.2016.03.005 · DOI · Paper page
- Zushi, 1998, STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells, Int. J. Cancer, 78, 326, 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4 · doi:10.1002/(sici)1097-0215(19981029)78:3<326::aid-ijc12>3.0.co;2-4
- Garcia, 1997, Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells, Cell Growth Differ., 8, 1267
- Plaza-Menacho, 2007, Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation, J. Biol. Chem., 282, 6415, 10.1074/jbc.M608952200 · DOI
- Tran, 2008, Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas, PLoS One, 3, e2125, 10.1371/journal.pone.0002125 · DOI
- Yeh, 2009, Ha-ras oncogene-induced Stat3 phosphorylation enhances oncogenicity of the cell, DNA Cell Biol., 28, 131, 10.1089/dna.2008.0762 · DOI
- Gough, 2009, Mitochondrial STAT3 supports Ras-dependent oncogenic transformation, Science, 324, 1713, 10.1126/science.1171721 · DOI · Paper page
- Kim, 2009, Targeted disruption of stat3 reveals a major role for follicular stem cells in skin tumor initiation, Cancer Res., 69, 7587, 10.1158/0008-5472.CAN-09-1180 · DOI
- Fukuda, 2011, Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression, Cancer Cell, 19, 441, 10.1016/j.ccr.2011.03.002 · DOI · Paper page
- Mace, 2015, Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer, Oncotarget, 6, 44509, 10.18632/oncotarget.6332 · DOI
- Gough, 2014, STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation, Blood, 124, 2252, 10.1182/blood-2013-02-484196 · DOI
- Yu, 2015, Mitochondrial STAT3 contributes to transformation of Barrett’s epithelial cells that express oncogenic Ras in a p53-independent fashion, Am. J. Physiol. Gastrointest. Liver Physiol., 309, G146, 10.1152/ajpgi.00462.2014 · DOI
- Saitoh, 2016, STAT3 integrates cooperative Ras and TGF-beta signals that induce Snail expression, Oncogene, 35, 1049, 10.1038/onc.2015.161 · DOI
- Yao, 2017, The FOXO 3-FOXM1 axis: a key cancer drug target and a modulator of cancer drug resistance, Semin. Cancer Biol.
- Koo, 1819, FOXM1: from cancer initiation to progression and treatment, Biochim. Biophys. Acta, 2012, 28
- Kalinichenko, 2015, Is there potential to target FOXM1 for ‘undruggable' lung cancers, Expert Opin. Ther. Targets, 19, 865, 10.1517/14728222.2015.1042366 · DOI
- Kopanja, 2015, Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features, J. Hepatol., 63, 429, 10.1016/j.jhep.2015.03.023 · DOI
- Pek, 2017, Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer, Oncogene, 36, 4975, 10.1038/onc.2017.120 · DOI · Paper page
- Park, 2009, FoxM1, a critical regulator of oxidative stress during oncogenesis, EMBO J., 28, 2908, 10.1038/emboj.2009.239 · DOI · Paper page
- Wang, 2014, Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D), Oncogene, 33, 5391, 10.1038/onc.2013.475 · DOI
- Eferl, 2003, AP-1: a double-edged sword in tumorigenesis, Nat. Rev. Cancer, 3, 859, 10.1038/nrc1209 · DOI · Paper page
- Mechta, 1997, Transformation by ras modifies AP1 composition and activity, Oncogene, 14, 837, 10.1038/sj.onc.1200900 · DOI · Paper page
- Zhang, 2017, Oncogenic RAS regulates long noncoding RNA orilnc1 in human cancer, Cancer Res., 77, 3745, 10.1158/0008-5472.CAN-16-1768 · DOI
- Cellurale, 2011, Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation, Mol. Cell. Biol., 31, 1565, 10.1128/MCB.01122-10 · DOI
- Yoshikawa, 2017, Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1alpha pathway, Cancer Lett., 410, 82, 10.1016/j.canlet.2017.09.017 · DOI
- Lim, 2004, Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion, Oncogene, 23, 9427, 10.1038/sj.onc.1208003 · DOI
- Zhang, 2017, Transcription factor Etv5 is essential for the maintenance of alveolar type II cells, Proc. Natl. Acad. Sci. U. S. A., 114, 3903, 10.1073/pnas.1621177114 · DOI
- Kar, 2013, Molecular mechanisms of ETS transcription factor-mediated tumorigenesis, Crit. Rev. Biochem. Mol. Biol., 48, 522, 10.3109/10409238.2013.838202 · DOI
- Zheng, 2013, Oncogene and non-oncogene addiction in inflammation-associated cancers, Future Oncol., 9, 561, 10.2217/fon.12.202 · DOI
- Borrello, 2008, Inflammation and cancer: the oncogene-driven connection, Cancer Lett., 267, 262, 10.1016/j.canlet.2008.03.060 · DOI
- Kitajima, 2016, Inflammation as a driver and vulnerability of KRAS mediated oncogenesis, Semin. Cell Dev. Biol., 58, 127, 10.1016/j.semcdb.2016.06.009 · DOI
- Ancrile, 2008, Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics, Mol. Interv., 8, 22, 10.1124/mi.8.1.6 · DOI
- Leibovich-Rivkin, 2014, The inflammatory cytokine TNFalpha cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells, BMC Cancer., 14, 158, 10.1186/1471-2407-14-158 · DOI
- Munoz, 2016, Oncogenic Ras modulates p38 MAPK-mediated inflammatory cytokine production in glioblastoma cells, Cancer Biol. Ther., 17, 355, 10.1080/15384047.2016.1139249 · DOI
- Catanzaro, 2014, Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4, Nat. Commun., 5, 3729, 10.1038/ncomms4729 · DOI
- Giannou, 2017, NRAS destines tumor cells to the lungs, EMBO Mol. Med., 9, 672, 10.15252/emmm.201606978 · DOI
- Gstaiger, 2001, Skp2 is oncogenic and overexpressed in human cancers, Proc. Natl. Acad. Sci. U. S. A., 98, 5043, 10.1073/pnas.081474898 · DOI · Paper page
- Kulinski, 2017, Dysregulated expression of SKP2 and its role in hematological malignancies, Leuk. Lymphoma, 1
- Lee, 2015, Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress, Mol. Cell, 57, 1022, 10.1016/j.molcel.2015.01.015 · DOI
- Delogu, 2015, SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice, Oncotarget, 6, 2222, 10.18632/oncotarget.2945 · DOI
- Latres, 2001, Role of the F-box protein Skp2 in lymphomagenesis, Proc. Natl. Acad. Sci. U. S. A., 98, 2515, 10.1073/pnas.041475098 · DOI · Paper page
- Schepers, 2005, Oncogenic Ras blocks transforming growth factor-beta-induced cell-cycle arrest by degradation of p27 through a MEK/Erk/SKP2-dependent pathway, Exp. Hematol., 33, 747, 10.1016/j.exphem.2005.04.006 · DOI
- Batlle, 2017, Cancer stem cells revisited, Nat. Med., 23, 1124, 10.1038/nm.4409 · DOI · Paper page
- Siveen, 2017, Targeting acute myeloid leukemia stem cell signaling by natural products, Mol. Cancer, 16, 13, 10.1186/s12943-016-0571-x · DOI · Paper page
- Moon, 2014, Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/beta-catenin signaling, J. Natl. Cancer Inst., 106, djt373, 10.1093/jnci/djt373 · DOI · Paper page
- Gierut, 2015, Oncogenic K-Ras promotes proliferation in quiescent intestinal stem cells, Stem Cell Res., 15, 165, 10.1016/j.scr.2015.06.003 · DOI
- Liu, 2009, p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo, Proc. Natl. Acad. Sci. U. S. A., 106, 19035, 10.1073/pnas.0910009106 · DOI · Paper page
- Xu, 2015, Let-7a regulates mammosphere formation capacity through Ras/NF-kappaB and Ras/MAPK/ERK pathway in breast cancer stem cells, Cell Cycle, 14, 1686, 10.1080/15384101.2015.1030547 · DOI
- Kim, 2010, Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer, Cancer Lett., 287, 172, 10.1016/j.canlet.2009.06.010 · DOI
- Yoon, 2011, The small GTPase Rac1 is involved in the maintenance of stemness and malignancies in glioma stem-like cells, FEBS Lett., 585, 2331, 10.1016/j.febslet.2011.05.070 · DOI
- Quinlan, 2008, Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion, Mol. Cell. Biol., 28, 2659, 10.1128/MCB.01661-07 · DOI
- Yang, 2008, Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer, PLoS One, 3, e2220, 10.1371/journal.pone.0002220 · DOI
- Okada, 2014, Targeting the K-Ras–JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation, Oncotarget, 5, 5100, 10.18632/oncotarget.2087 · DOI
200 of 207 shown
Cited by
Neuroprotective Effects of Quercetin in Alzheimer’s Disease
Khan, H., Ullah, H., Aschner, M., Cheang, W. S., & Akkol, E. K. (2019) · Biomolecules · doi:10.3390/biom10010059 · Cited by 537
The biology and treatment of Merkel cell carcinoma: current understanding and research priorities
on behalf of the International Workshop on Merkel Cell Carcinoma Research (IWMCC) Working Group, Harms, P. W., Harms, K. L., Moore, P. S., DeCaprio, J. A., Nghiem, P., Wong, M. K. K., & Brownell, I. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0103-2 · Cited by 316
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 308
A Comparative Analysis of Individual RAS Mutations in Cancer Biology
Muñoz-Maldonado, C., Zimmer, Y., & Medová, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01088 · Cited by 254
Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., & Wei, X. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.006 · Cited by 212
Metadata
- Authors
- Khan, A. Q., Kuttikrishnan, S., Siveen, K. S., Prabhu, K. S., Shanmugakonar, M., Al- Naemi, H. A., Haris, M., Dermime, S., & Uddin, S.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 54
- Pages
- 1-13
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2793577044
- Cited by
- 179
- References
- 27
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- Medical Research Center (16354/16)
- Hamad Medical Corporation, Doha, State of Qatar
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.